{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:57:34Z","timestamp":1768276654305,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-02839-y","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T10:02:26Z","timestamp":1710756146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systematic review of randomized controlled trials of topicals for actinic keratosis field therapy"],"prefix":"10.1007","volume":"316","author":[{"given":"Paras","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bitterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Mineroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Jagdeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"3","key":"2839_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jaad.2020.03.126","volume":"83","author":"TJ Willenbrink","year":"2020","unstructured":"Willenbrink TJ et al (2020) Field cancerization: definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol 83(3):709\u2013717","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2839_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s13671-019-00265-2","volume":"8","author":"A Huang","year":"2019","unstructured":"Huang A et al (2019) Updates on treatment approaches for cutaneous field cancerization. Curr Dermatol Rep 8(3):122\u2013132","journal-title":"Curr Dermatol Rep"},{"issue":"6","key":"2839_CR3","first-page":"415","volume":"97","author":"J Lanoue","year":"2016","unstructured":"Lanoue J, Chen C, Goldenberg G (2016) Actinic keratosis as a marker of field cancerization in excision specimens of cutaneous malignancies. Cutis 97(6):415\u2013420","journal-title":"Cutis"},{"key":"2839_CR4","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.12837.1","author":"SR Christensen","year":"2018","unstructured":"Christensen SR (2018) Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.12837.1","journal-title":"F1000Res"},{"issue":"10","key":"2839_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW et al (2015) Incidence estimate of nonmelanoma skin cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol 151(10):1081\u20131086","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2839_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jdv.14652","volume":"32","author":"I Figueras Nart","year":"2018","unstructured":"Figueras Nart I et al (2018) Defining the actinic keratosis field: a literature review and discussion. J Eur Acad Dermatol Venereol 32(4):544\u2013563","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2839_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1590\/abd1806-4841.20132300","volume":"88","author":"LA Torezan","year":"2013","unstructured":"Torezan LA, Festa-Neto C (2013) Cutaneous field cancerization: clinical, histopathological and therapeutic aspects. An Bras Dermatol 88(5):775\u2013786","journal-title":"An Bras Dermatol"},{"issue":"9","key":"2839_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/jamadermatol.2020.2427","volume":"156","author":"S Cheraghlou","year":"2020","unstructured":"Cheraghlou S, Feng H, Cohen JM (2020) Trends in the access and cost of photodynamic therapy among Medicare beneficiaries in the United States, 2012\u20132017. JAMA Dermatol 156(9):1021\u20131022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2839_CR9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/bjd.18884","volume":"183","author":"MHE Jansen","year":"2020","unstructured":"Jansen MHE et al (2020) A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands. Br J Dermatol 183(4):738\u2013744","journal-title":"Br J Dermatol"},{"key":"2839_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/TCRM.S12498","volume":"7","author":"CG Nelson","year":"2011","unstructured":"Nelson CG (2011) Diclofenac gel in the treatment of actinic keratoses. Ther Clin Risk Manag 7:207\u2013211","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"2839_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.141.4.467","volume":"141","author":"N Korman","year":"2005","unstructured":"Korman N et al (2005) Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141(4):467\u2013473","journal-title":"Arch Dermatol"},{"issue":"1","key":"2839_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.36849\/JDD.5328","volume":"20","author":"CE Heron","year":"2021","unstructured":"Heron CE, Feldman SR (2021) Ingenol mebutate and the treatment of actinic keratosis. J Drugs Dermatol 20(1):102\u2013104","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"2839_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.36849\/JDD.6078","volume":"20","author":"JD Rosso","year":"2021","unstructured":"Rosso JD et al (2021) Advances and considerations in the management of actinic keratosis: an expert consensus panel report. J Drugs Dermatol 20(8):888\u2013893","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"2839_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MHE Jansen","year":"2019","unstructured":"Jansen MHE et al (2019) Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med 380(10):935\u2013946","journal-title":"N Engl J Med"},{"key":"2839_CR15","unstructured":"Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009). Centre for Evidence Based Medicine 2009. cited 7 Aug 2023."},{"key":"2839_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.658636","volume":"11","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S et al (2021) 5-Fluorouracil: a narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent. Front Oncol 11:658636","journal-title":"Front Oncol"},{"issue":"1","key":"2839_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-016-0161-2","volume":"7","author":"E Stockfleth","year":"2017","unstructured":"Stockfleth E et al (2017) Efficacy and safety of 5-fluorouracil 0.5%\/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. Dermatol Ther (Heidelb) 7(1):81\u201396","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"2839_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","volume":"165","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth E et al (2011) Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165(5):1101\u20131108","journal-title":"Br J Dermatol"},{"issue":"6","key":"2839_CR19","first-page":"335","volume":"70","author":"J Jorizzo","year":"2002","unstructured":"Jorizzo J et al (2002) Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 70(6):335\u2013339","journal-title":"Cutis"},{"issue":"6","key":"2839_CR20","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0149-2918(02)80012-1","volume":"24","author":"K Loven","year":"2002","unstructured":"Loven K et al (2002) Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24(6):990\u20131000","journal-title":"Clin Ther"},{"issue":"11","key":"2839_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","volume":"40","author":"JE Wolf Jr","year":"2001","unstructured":"Wolf JE Jr et al (2001) Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 40(11):709\u2013713","journal-title":"Int J Dermatol"},{"issue":"5","key":"2839_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12672","volume":"31","author":"C Mazzella","year":"2018","unstructured":"Mazzella C et al (2018) Management of clinical and subclinical actinic keratoses with histological and immunohistochemical assessments by confocal microscopy. Dermatol Ther 31(5):e12672","journal-title":"Dermatol Ther"},{"issue":"1","key":"2839_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000254893","volume":"220","author":"M Ulrich","year":"2010","unstructured":"Ulrich M et al (2010) Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology 220(1):15\u201324","journal-title":"Dermatology"},{"issue":"1","key":"2839_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","volume":"146","author":"JK Rivers","year":"2002","unstructured":"Rivers JK et al (2002) Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146(1):94\u2013100","journal-title":"Br J Dermatol"},{"issue":"8","key":"2839_CR25","first-page":"46","volume":"3","author":"GK Kim","year":"2010","unstructured":"Kim GK (2010) The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in? J Clin Aesthet Dermatol 3(8):46\u201353","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"2839_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1172\/JCI89820","volume":"127","author":"TJ Cunningham","year":"2017","unstructured":"Cunningham TJ et al (2017) Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest 127(1):106\u2013116","journal-title":"J Clin Invest"},{"issue":"4","key":"2839_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/0253-7613.161249","volume":"47","author":"AK Bubna","year":"2015","unstructured":"Bubna AK (2015) Imiquimod\u2014its role in the treatment of cutaneous malignancies. Indian J Pharmacol 47(4):354\u2013359","journal-title":"Indian J Pharmacol"},{"issue":"Suppl 2","key":"2839_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2133.2007.08269.x","volume":"157","author":"C Ulrich","year":"2007","unstructured":"Ulrich C et al (2007) Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 157(Suppl 2):25\u201331","journal-title":"Br J Dermatol"},{"issue":"4","key":"2839_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1046\/j.1440-0960.2003.00003.x","volume":"44","author":"K Chen","year":"2003","unstructured":"Chen K et al (2003) Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol 44(4):250\u2013255","journal-title":"Australas J Dermatol"},{"issue":"4","key":"2839_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","volume":"62","author":"N Swanson","year":"2010","unstructured":"Swanson N et al (2010) Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 62(4):582\u2013590","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2839_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","volume":"57","author":"J Jorizzo","year":"2007","unstructured":"Jorizzo J et al (2007) Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 57(2):265\u2013268","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2839_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","volume":"157","author":"A Alomar","year":"2007","unstructured":"Alomar A, Bichel J, McRae S (2007) Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 157(1):133\u2013141","journal-title":"Br J Dermatol"},{"issue":"4","key":"2839_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","volume":"51","author":"RM Szeimies","year":"2004","unstructured":"Szeimies RM et al (2004) Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 51(4):547\u2013555","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2839_CR34","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/j.1365-2133.2009.09260.x","volume":"161","author":"K Gebauer","year":"2009","unstructured":"Gebauer K, Shumack S, Cowen PS (2009) Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol 161(4):897\u2013903","journal-title":"Br J Dermatol"},{"issue":"9","key":"2839_CR35","first-page":"986","volume":"14","author":"M Carducci","year":"2015","unstructured":"Carducci M et al (2015) Comparative effects of sunscreens alone vs sunscreens plus DNA repair enzymes in patients with actinic keratosis: clinical and molecular findings from a 6-month, randomized. Clinical Study J Drugs Dermatol 14(9):986\u2013990","journal-title":"Clinical Study J Drugs Dermatol"},{"issue":"4","key":"2839_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/phpp.12452","volume":"35","author":"I Bobyr","year":"2019","unstructured":"Bobyr I et al (2019) Fluorescent photodiagnostic evaluation of field cancerization treated with a medical device containing piroxicam 08% and sunscreen SPF 50+ for actinic keratosis. Photodermatol Photoimmunol Photomed 35(4):277\u2013279","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"2","key":"2839_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.abd.2021.06.005","volume":"97","author":"BA Alvares","year":"2022","unstructured":"Alvares BA et al (2022) Efficacy of sunscreen with photolyase or regular sunscreen associated with topical antioxidants in treating advanced photodamage and cutaneous field cancerization: a randomized clinical trial. An Bras Dermatol 97(2):157\u2013165","journal-title":"An Bras Dermatol"},{"issue":"6","key":"2839_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/phpp.12597","volume":"36","author":"H Luze","year":"2020","unstructured":"Luze H et al (2020) DNA repair enzymes in sunscreens and their impact on photoageing-A systematic review. Photodermatol Photoimmunol Photomed 36(6):424\u2013432","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"10 Suppl 1","key":"2839_CR39","first-page":"S3","volume":"15","author":"B Berman","year":"2022","unstructured":"Berman B, Grada A, Berman DK (2022) Profile of tirbanibulin for the treatment of actinic keratosis. J Clin Aesthet Dermatol 15(10 Suppl 1):S3\u2013S10","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"2839_CR40","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1056\/NEJMoa2024040","volume":"384","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A et al (2021) Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med 384(6):512\u2013520","journal-title":"N Engl J Med"},{"issue":"1","key":"2839_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s40800-017-0068-6","volume":"5","author":"P Kishi","year":"2018","unstructured":"Kishi P, Price CJ (2018) Life-threatening reaction with topical 5-fluorouracil. Drug Saf Case Rep 5(1):4","journal-title":"Drug Saf Case Rep"},{"issue":"8","key":"2839_CR42","first-page":"2006","volume":"5","author":"MR Johnson","year":"1999","unstructured":"Johnson MR et al (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5(8):2006\u20132011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2839_CR43","first-page":"1531","volume":"34","author":"P Papanastasopoulos","year":"2014","unstructured":"Papanastasopoulos P, Stebbing J (2014) Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res 34(4):1531\u20131535","journal-title":"Anticancer Res"},{"key":"2839_CR44","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/ijd.14824","volume":"59","author":"SA-O Suh","year":"2020","unstructured":"Suh SA-O et al (2020) The banned sunscreen ingredients and their impact on human health: a systematic review. Int J Dermatol 59:1365\u20134632","journal-title":"Int J Dermatol"},{"issue":"7","key":"2839_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1600-0625.2009.01047.x","volume":"19","author":"JP Ortonne","year":"2010","unstructured":"Ortonne JP et al (2010) Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol 19(7):641\u2013647","journal-title":"Exp Dermatol"},{"issue":"6","key":"2839_CR46","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/ced.15136","volume":"47","author":"C Baker","year":"2022","unstructured":"Baker C et al (2022) Method of Assessing Skin Cancerization and Keratoses(TM) (MASCK): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerization. Clin Exp Dermatol 47(6):1144\u20131153","journal-title":"Clin Exp Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02839-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:05:04Z","timestamp":1712667904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02839-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2839"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02839-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"108"}}